(NYSE: RDY) Dr Reddys Laboratories's forecast annual revenue growth rate of 7.7% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.44%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.66%.
Dr Reddys Laboratories's revenue in 2023 is $2,988,320,369.On average, 2 Wall Street analysts forecast RDY's revenue for 2024 to be $546,477,045,242, with the lowest RDY revenue forecast at $543,067,386,981, and the highest RDY revenue forecast at $549,886,703,503. On average, 2 Wall Street analysts forecast RDY's revenue for 2025 to be $585,415,425,848, with the lowest RDY revenue forecast at $583,681,870,659, and the highest RDY revenue forecast at $587,148,981,037.
In 2026, RDY is forecast to generate $621,069,044,100 in revenue, with the lowest revenue forecast at $621,050,726,033 and the highest revenue forecast at $621,087,362,166.